Case Report: Neoadjuvant PD-1 Blockade Plus Concurrent Chemoradiotherapy in Unresectable Locally Advanced Gastric...

Area of Science:

• Oncology
• Immunotherapy
• Gastrointestinal Oncology

Background:

• Advanced gastric cancer presents significant treatment challenges.
• Neoadjuvant therapy aims to improve resectability and patient outcomes.
• Programmed death 1 (PD-1) blockade is an emerging immunotherapy strategy.

Observation:

• A retrospective analysis included three patients with locally advanced gastric cancer.
• Patients received neoadjuvant sintilimab (a PD-1 inhibitor) plus concurrent chemoradiotherapy.
• Surgical gastrectomy was performed after a median of 3.9 months post-treatment.

Findings:

• The neoadjuvant sintilimab and chemoradiotherapy regimen exhibited an acceptable side-effect profile.
• Two out of three patients achieved a major pathological response.
• One patient achieved a pathologic complete response.

Implications:

• PD-1 blockade combined with chemoradiotherapy is a potentially effective neoadjuvant strategy for unresectable locally advanced gastric cancer.
• This combination therapy warrants further investigation in larger clinical trials.
• Optimizing neoadjuvant treatment could improve survival rates for gastric cancer patients.